BCL2 and Sepsis: Given that the BCL2 BH4-domain proteins themselves do not appear to elicit a pro-inflammatory response [26](Table S2), as is observed with many other DAMPs, it is possible that extracellular administration of rhBCL2 or rhBCL2A1 protein may offer a new approach to therapy of sepsis.